Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, biopsy, and various therapies. Combining therapies with complementary ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications. The Hugo™ robotic-assisted surgery (RAS) system is safe and effective, ...

Universal genetic testing at an institution identified pathogenic germline variants in 14% of patients with genitourinary cancer. More than 1 in 8 patients with genitourinary malignancies in a recent ...

FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...

Detalimogene voraplasmid is a novel, investigational, pivotal-stage, non-viral genetic medicine designed to mitigate systemic risks and deliver durable efficacy for patients with high-risk NMIBC, ...

Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer We retrospectively analyzed ...